Seattle Genetics, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SGEN Nasdaq 8731 http://www.seattlegenetics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Seattle Genetics, Inc.

Seattle Genetics searches for its 10th building to keep up with growth - Apr 19th, 2018 3:28 pm
Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting - Apr 12th, 2018 6:00 am
See what the IHS Markit Score report has to say about Seattle Genetics Inc. - Apr 5th, 2018 6:08 am
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018 - Apr 5th, 2018 6:00 am
Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion - Mar 28th, 2018 3:02 pm
Key Updates on Akcea Therapeutics’ Volanesorsen - Mar 27th, 2018 7:01 am
Seattle Genetics wins FDA approval for cancer drug that could push U.S. sales past $1 billion - Mar 26th, 2018 3:53 pm
A Look at Ionis’s Key Revenue Drivers in 4Q17 - Mar 26th, 2018 9:15 am
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - Mar 26th, 2018 6:00 am
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - Mar 26th, 2018 6:00 am
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus - Mar 23rd, 2018 8:28 am
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion - Mar 21st, 2018 8:55 am
Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval - Mar 20th, 2018 12:10 pm
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma - Mar 20th, 2018 10:48 am
Seattle Genetics adds second woman to its board with the appointment of Alpna Seth - Mar 16th, 2018 1:15 pm
Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors - Mar 15th, 2018 6:00 am
Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018 - Mar 13th, 2018 6:00 am
Is Celldex Therapeutics Stock About to Skyrocket? - Mar 13th, 2018 4:32 am
Seattle Genetics Completes Acquisition of Cascadian Therapeutics - Mar 9th, 2018 7:26 am